Orphazyme raises eur 14 miollion to further expand its clinical development programme

Orphazyme raises eur 14 miollion to further expand its clinical development programme

Date
March 9, 2017

Copenhagen March 9, 2017

Orphazyme ApS today announced the successful completion of a EUR 14M financing round. Two new investors, LSP and the ALS Investment Fund joins the investor syndicate comprising Kurma Partners, Idinvest Partners, Novo A/S, Sunstone Capital and Aescap Venture.

Novo Holdings uses cookies to ensure that we give you the best experience on our website. Read more